EUCTR2014-002007-13-ES进行中（未招募）1 期
A multicenter, randomized, placebo-controlled, double-blind and crossover pilot trial with human alpha-1 antitrypsin in patients with chronic fatigue syndrome
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female aged 18 to 65 years.
- •2.Subjects with a BMI ? 30 Kg/m2.
- •3.Subjects who meet ?Myalgic Encephalomyelitis: International Consensus Criteria, 2011? and with a diagnostics of CFS for more than 12 months.
- •4.Subjects who understand and voluntarily signed by written his/her clinical trial participation consent.
- •5.Subjects who judged to be reliable and demonstrated a degree of understanding that allowed them to communicate intelligibly, according to the investigator?s criteria, so it can be successfully applied the monitoring clinical instruments of CFS proposed in the clinical trial.
- •6.Subjects must be willing to comply with all aspects of the clinical trial protocol, including blood sampling and limitation in medication to alleviate CFS-symptoms.
- •7.Subjects who have successfully completed the Screening Period.
- •8.Subjects with elastase activity in PBMC exceeding 150 units/mg prior to start Run-in Period (Week -6).
- •9.Subjects who have successfully completed the Run-in Period.
- •10.Subjects with elastase activity in PBMC exceeding 150 units/mg at the Baseline Visit 1 (Week 0).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •1.Subjects with any severe congenital deficiency of AAT.
- •2.Subjects who are active smokers within 6 months prior to Enrollment Visit.
- •3.Subjects currently receiving, or having received within 3 months prior to the Enrollment Visit treatment with human AAT.
- •4.Subjects with a history of intolerance to any component or excipient of the investigational products (AAT, chloride, phosphate, sodium).
- •5.Subjects with a history of anaphylactic reactions or severe reactions to any blood-derived product.
- •6.Subjects with a history of chronic alcoholism or illicit drug abuse (addiction) in the preceding 12 months prior to the Enrollment Visit.
- •7.Subjects with a known selective IgA deficiency and serum antibodies anti-IgA.
- •8.Subjects with any medical condition in the moment of the Enrollment Visit determined by laboratory tests, which is likely to significantly interfere in the clinical manifestation of CFS. Here are detailed some of these medical conditions:
- •?Serum AST, ALT, ALP or total bilirubin levels exceeding more than 1.5 times the upper limit of normal (ULN) for the expected normal range for the testing laboratory.
- •?Serum creatinine or urea levels exceeding more than 1.5 time the ULN for the expected normal range for the testing laboratory.
- •?Serum CK totals levels exceeding the ULN for the expected normal range for the testing laboratory.
- •?Serum TSH levels exceeding the ULN for the expected normal range for the testing laboratory.
- •?Serum title of ANA exceeding 1:160 dilutions.
- •?Positive serum FR as per positivity criteria established for the testing laboratory.
- •9.Subjects suffering from a disease or medical condition that could increase associated risks to subjects? participation in the clinical trial, or interfere with the interpretation of the study results, and according to the investigator?s criteria, it would be inappropriate for the subjects? participation in the clinical trial. These diseases include, but are not limited to major depressive disorders with psychotic or melancholic features as bipolar disorders, schizophrenia, dementia, anorexia or nervous bulimia.
- •10.Subjects currently receiving, or have received within 3 months prior to the Enrollment Visit, any investigational medicinal product or device.
- •11.Females who are pregnant, breastfeeding, of child-bearing potential, or unwilling to practice a highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence*) throughout the study.
- •* True abstinence: When this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods], declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception.)
- •12.Subjects pending for a resolution of a dispute or compensatory process, caused by their medical condition.
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDpolycystic kidney diseaseMedDRA version: 8.1Level: LLTClassification code 10011771Term: Cystic kidney diseaseEUCTR2006-001485-16-FRovartis Pharma GmbH300
进行中（未招募）
1 期
immunoglobulin infusion as adjuvant therapy in patients with Pemphigus VulgarisEUCTR2013-000211-24-DERuprecht-Karls-University Heidelberg10
进行中（未招募）
不适用
A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDEUCTR2006-001485-16-ATovartis Pharma GmbH300
招募中
不适用
Evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg compared with each monotherapyEndocrine, nutritional and metabolic diseaseKCT0001405G Life Sciences285
进行中（未招募）
2 期
A study of JNJ-64042056 in participants with preclinical Alzheimer's diseasePreclinical Alzheimer’s DiseaseNervous System DiseasesISRCTN78730935Janssen-Cilag International NV498